Literature DB >> 26923201

Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis.

Guangqi Song1, Martin Pacher2, Asha Balakrishnan2, Qinggong Yuan2, Hsin-Chieh Tsay3, Dakai Yang4, Julia Reetz5, Sabine Brandes2, Zhen Dai4, Brigitte M Pützer5, Marcos J Araúzo-Bravo6, Doris Steinemann7, Tom Luedde8, Robert F Schwabe9, Michael P Manns10, Hans R Schöler11, Axel Schambach12, Tobias Cantz13, Michael Ott14, Amar Deep Sharma15.   

Abstract

Direct induction of induced hepatocytes (iHeps) from fibroblasts holds potential as a strategy for regenerative medicine but until now has only been shown in culture settings. Here, we describe in vivo iHep formation using transcription factor induction and genetic fate tracing in mouse models of chronic liver disease. We show that ectopic expression of the transcription factors FOXA3, GATA4, HNF1A, and HNF4A from a polycistronic lentiviral vector converts mouse myofibroblasts into cells with a hepatocyte phenotype. In vivo expression of the same set of transcription factors from a p75 neurotrophin receptor peptide (p75NTRp)-tagged adenovirus enabled the generation of hepatocyte-like cells from myofibroblasts in fibrotic mouse livers and reduced liver fibrosis. We have therefore been able to convert pro-fibrogenic myofibroblasts in the liver into hepatocyte-like cells with positive functional benefits. This direct in vivo reprogramming approach may open new avenues for the treatment of chronic liver disease.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26923201     DOI: 10.1016/j.stem.2016.01.010

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  66 in total

1.  In Vivo Interplay between p27Kip1, GATA3, ATOH1, and POU4F3 Converts Non-sensory Cells to Hair Cells in Adult Mice.

Authors:  Bradley J Walters; Emily Coak; Jennifer Dearman; Grace Bailey; Tetsuji Yamashita; Bryan Kuo; Jian Zuo
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

2.  Cardiac reprogramming factor Gata4 reduces postinfarct cardiac fibrosis through direct repression of the profibrotic mediator snail.

Authors:  Megumi Mathison; Vivek P Singh; Deepthi Sanagasetti; Lina Yang; Jaya Pratap Pinnamaneni; Jianchang Yang; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2017-06-21       Impact factor: 5.209

3.  Novel methods for the treatment of liver fibrosis using in vivo direct reprogramming technology.

Authors:  Takeshi Goya; Atsushi Suzuki
Journal:  Stem Cell Investig       Date:  2016-12-09

Review 4.  Gene therapy approaches in the non-human primate model of Parkinson's disease.

Authors:  D Pignataro; D Sucunza; A J Rico; I G Dopeso-Reyes; E Roda; A I Rodríguez-Perez; J L Labandeira-Garcia; V Broccoli; S Kato; K Kobayashi; José L Lanciego
Journal:  J Neural Transm (Vienna)       Date:  2017-01-27       Impact factor: 3.575

5.  In vivo reprogramming of hepatic myofibroblasts into hepatocytes attenuates liver fibrosis: back to the future?

Authors:  Erica Novo; Stefania Cannito; Maurizio Parola
Journal:  Stem Cell Investig       Date:  2016-09-29

6.  Assessment of engineered cells using CellNet and RNA-seq.

Authors:  Arthur H Radley; Remy M Schwab; Yuqi Tan; Jeesoo Kim; Emily K W Lo; Patrick Cahan
Journal:  Nat Protoc       Date:  2017-04-27       Impact factor: 13.491

7.  Wound healing and fibrosis: current stem cell therapies.

Authors:  Ruth Ellen Jones; Deshka S Foster; Michael S Hu; Michael T Longaker
Journal:  Transfusion       Date:  2019-02       Impact factor: 3.157

8.  Liver: Hepatocytes induced from myofibroblasts in vivo.

Authors:  Charlotte Ridler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-06       Impact factor: 46.802

Review 9.  In Vivo Cellular Reprogramming: The Next Generation.

Authors:  Deepak Srivastava; Natalie DeWitt
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

Review 10.  Emerging advancements in liver regeneration and organogenesis as tools for liver replacement.

Authors:  Stacey S Huppert; Kathleen M Campbell
Journal:  Curr Opin Organ Transplant       Date:  2016-12       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.